Product Specification Sheet

Product Name: BMS-232632 (Atazanavir)
Catalog Number: C2232

Technical information:

- **Chemical Formula:** C_{38}H_{52}N_{6}O_{7}
- **CAS #:** 198904-31-3, 229975-97-7
- **Molecular Weight:** 704.86
- **Purity:** > 99%
- **Appearance:** White solid
- **Solubility:** Soluble in DMSO up to 100 mM
- **Chemical Name:** 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (35,85,95,12S)-
- **Storage:** Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.
- **Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

Handling:
- To make 10 mM stock solution, add 0.142mL of DMSO for each mg of BMS-232632 (Atazanavir)
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

Biological Activity:

Atazanavir (BMS-232632) is an orally available, azapeptide human immunodeficiency virus type 1 (HIV-1) protease inhibitor with EC50 of 2.6-5.3 nM, and EC90 of 9-15 nM. [1] Atazanavir has been shown to be effective in HIV-1 strains resistant to other antivirals such as nelfinavir, saquinavir, and amprenavir. Additionally, indinavir- and ritonavir-resistant strains are more six- to nine-fold more sensitive to atazanavir.

Atazanavir’s is highly selective for HIV-1 protease and only exhibits cytotoxic effects in 6500- to 23000-fold higher concentrations than is required for anti-HIV activity. Atazanavir has been shown to be additive or synergistic with a number of different antiviral therapies without antagonistic anti-HIV activity or cytotoxicity. [2, 3]

Reference:
2. Robinson et al., BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrobial Agents Chemother. 2000, 44(8), 2093-2099. Pubmed ID: 10898681
3. Colombo et al., Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrobial Agents Chemother. 2003, 47(4), 1324-1333. Pubmed ID: 12654666

For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

Chemicals are sold for research use only, not for clinical or diagnostic use.